Impact ledger
Align Technology, Inc. (ALGN): the developments shaping its investment case
Follow the evidence affecting Align Technology, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Align Technology, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-09
Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook
Channel: Indirect competitive read-through. Dentsply Sirona's maintained guidance in a related dental market could suggest either stable market demand or competitive pressures, depending on segment overlap.
mixed· 1-3m
2026-09-09 · 3 reports
Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance
Channel: Indirect read-through on dental industry demand and competitive landscape.
watch· 1-3m
2026-09-27
Staar Surgical initiates $50M share repurchase program, lifting stock 7.5%
Channel: Indirect peer comparison; STAA's confidence in its market and financial position might suggest similar underlying strength or competitive dynamics in the broader medical device/ophthalmology sector, potentially influencing investor sentiment for peers.
watch· 1-3m
Event impact log
6 events mapped to ALGN since 2026-09-09. Evidence through 2026-09-27.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-27 | Staar Surgical initiates $50M share repurchase program, lifting stock 7.5% | Indirect peer comparison; STAA's confidence in its market and financial position might suggest similar underlying strength or competitive dynamics in the broader medical device/ophthalmology sector, potentially influencing investor sentiment for peers. | watch | 1-3m | 0.30 |
| 2026-09-27 | Staar Surgical Rallies 7.5% Following Board Approval of $50 Million Buyback Program | Indirectly, as a peer in the medical device/ophthalmology space, STAA's capital allocation strategy might set a precedent or highlight investor expectations for similar companies with strong balance sheets. | watch | 3-12m | 0.30 |
| 2026-09-09 | Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance | Indirect read-through on dental industry demand and competitive landscape. | watch | 1-3m | 0.30 |
| 2026-09-09 | Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance | Indirect read-through on dental equipment and consumables market demand. Dentsply Sirona's overall revenue contraction could signal broader industry headwinds, though specific segment growth (Wellspect) suggests nuanced market dynamics. | watch | 1-3m | 0.30 |
| 2026-09-09 | Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook | Indirect read-through on dental industry demand and competitive landscape. | mixed | 1-5d | 0.40 |
| 2026-09-09 | Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook | Indirect competitive read-through. Dentsply Sirona's maintained guidance in a related dental market could suggest either stable market demand or competitive pressures, depending on segment overlap. | mixed | 1-3m | 0.40 |
Continue this research
Build your Align Technology, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the ALGN entity page →